Evaluation of circulating immune complexes in lymphomas and leukemias using two different assays.
Circulating immune complexes (CICs) have been detected in the sera of patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease, chronic myeloid leukemia, and acute lymphoblastic leukemia by using C1q-binding and L1210-binding assays. Both assays gave broadly similar patterns of reactivity in terms of frequency and magnitude, though there are some differences. Significantly elevated CIC levels were observed in all pathologic groups. However, sera from NHL patients with an unfavorable prognosis consistently exhibited the highest frequency of positive values and mean CIC levels in both these assays. The two tests showed concordance in 66.6% of the NHL patients' sera and were significantly correlated. Of the sera from NHL patients 12.7% were positive in the C1q-binding assay only and 15.9% in the L1210-binding assay only. Both the assays gave positive results in some patients, and a degree of overlap indicates the presence of different types of CIC in cancer patients' sera. The combined use of two methods for detecting CICs may be useful for evaluation of the activity, the extent, and the prognosis of the malignant disease.
D000818:Animals; D000936:Antigen-Antibody Complex / Q000032:analysis*; D003166:Complement Activating Enzymes / Q000378:metabolism; D015922:Complement C1q; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007938:Leukemia / Q000276:immunology*; D007939:Leukemia L1210 / Q000276:immunology; D008223:Lymphoma / Q000276:immunology*
D000936:Antigen-Antibody Complex; D015922:Complement C1q; D003166:Complement Activating Enzymes